This board sure got quiet. Is the stock trading?

MLNT board now available on iHub.

Agreed...Nothing for me to do is hunker down over the smoking remains and hope like crazy that the new admin is a heck of a lot more competent than the last. However ambivalent i may be about it.
I'm too far underwater here, and too stubborn to comfortably walk away.
The potential is there, but.....

Have to look at this as a new company now. The Cemp management is gone, as you stated.

Soli can still be the Golden Goose. Just have to look at this as any other company that PPS crapped out. I just look at this compared to another Biotech..

For instance, can VTGN go to 15 before this goes to 250. Both will have dilution but within 15 months VTGN could be up 1500%

I am not down here personally as I did not like when she decided to hire a salesforce and then do the raises with JP. But my family is down 1/2 mil big ones currently if I don't factor in trading gains.

If you reset here and BARDA actually does come in and fund Soli this could be score.

On the optimistic side, if one treats this as a brand new company, Melinta could see a pretty good spike if Barda funds the Soli trial.

For one, it is well established this is a new class antibiotic and is incredibly effective.

The liver issues are most likely overblown. I am not to high on Baxdela being launched and I doubt they will reach projected 400 mil in sales within 3 to 5 years but by the time Soli is approved they will have a seasoned sales force.

Within a year they will need more money, a couple hundred mil doesn’t last long when you launch a new drug.

There are other small catalysts that could help the news cycle but Soli is still the prize.

When they announced the deal the stock was at 4. Post reverse split would be 20.

When they evaluated deal they stated combined company would be worth 10, which is 50 post split

Stock is under 12 and will most likely be under 10 shortly and they will piss 200 million away, unless they get very very lucky

Freakin losers. Lucky we sold. Friends lost millions

CEPM implements 1:5 reverse split in conjunction with closing of the reverse merger:

#msg-135952824

One advantage to the merger is that we shed the present management plague, if at great cost.
We might end up with a small interest in a company with an approved, needed, product on the market and management clever enough to pull off a merger from a disadvantageous position.
Perhaps they can then get our stuff approved too.
Isn't that a good attitude? sigh

Agreed. Think it might go lower but maybe get a bounce. Not worth it for me to add considering some of the other low priced issues I am in right now with short term catalysts on the way.

To bad, I loved Soli. Bad management can f up even the best products/drugs

The whole flaming thing is unforgivable.
People are suffering horribly while they maneuver to line their pockets with the stockholder's hopes and $.
Criminal behavior is an understatement!

The Flaming Bag of Sh*t Melinta, the company CEMP is merging with received an audit letter that they could not proceed as a going return, look at auditors report.

And these blowhards CEMP with 175 million in cash give them a sweetheart deal and give themselves huge golden parachutes

Here is the link to shareholder lawsuit...These guys almost give Keith Berman from DECN a run for the money for being scumbags

https://s3.amazonaws.com/bbemail/PROD/ulib/3d0u1e/docs/4d2967f4-159d-10d0-5153-be1780a8d256/Cemp.pdf

Lawsuit was filed against Cemp today. Temporary CEO gave himself 1.8 million dollar golden parachute if deal goes through.

8 mil penalty if deal doesn’t go through, unheard of with a private company merge like this.

Add the 8 mil and they could have wasted 12 million plus if this gets torpedoed, which it should

Assuming the Soli is worthless, which it is not, this should be worth 7 dollars just on cash, tax loss and being a public entity.

If they have a funding source for Soli that makes this even more bizarre.

Applause!
As a shareholder, it's hard not to take it personally.
I wonder if the SEC has any teeth left?

Pretty disgusted!
Lame business majors with no interest in the science nor saving lives!
Fiscal duty to the shareholders has been abandoned completely.
It shouldn't take more than about 15 minutes before the legal actions begin to flood in and swamp what remains.
I only wish the legal attack could be restricted to admin personally.

New lows for these bozos

Shub, a friend of mine followed my lead. I contacted the SEC regarding another company and there is now an investigation. He contacted SEC 4 weeks ago and was responded to this afternoon.

An investigator is making an appointment to go over the CEMP issues


This is ridiculous!

You are right. These pecker heads are self serving.

Cash equal 3.40

PPS. 2.40


That about sums up these scumbags

Just read the first pages of the telephone book merger proposal and proxy; and came away gritting my teeth.
Management looks extremely self serving at our expense.
I'm voting no, even if it folds the company..
The proxy proposal looks profoundly ugly.

Hard to believe the market isn’t excited about this merger. It is a shareholder fleecing.

Why isn’t the company having a call explaining this deal with analysts. If they did that real questions could be asked. The timing of proxy mail before a holiday using snail mail.

Morgan Stanley asked only softball questions and they stand to make 4.5 million of deal goes through.

What are they hiding. Stock currently trades below cash yet they valued this at 10 bucks a share.

Cemp meeting November 3

why all the selling?

Something's must have been disclosed at last nights conference

Big difference between the market underpricing a merger and the stock trading at 70% discount to a combined merge value. More like the market is calling Bullsh*t

Back from vacation and this pig is still barely holding 3 even though the merge is evaluated at 10.

MS just valued the deal. The good folks at Cemp misrepresented on the phone that MS looked at over 100 business opportunities and that is not the case.

It's to bad as I would like to load up but management seems like dummies still. A good drug could make even dummies look smart though

"..Looks like Morgan Stanley, who put this deal together couldn't get many interested at the Morgan stanley event. Unreal"

Inferring it's apt to fall apart? That'd be fine with me.

"That firm is a class action firm."

All they do is steal money from hapless investors. (Well...) Go and see if that firm ever made one cent. (Well...)


"As far as the pharma offer, it is odd that there was not a follow up. if a pharma was serious they would not make an offer without DD including really taking a deep dive into all the data from the studies."

I can see a scenario where an exec asked Dr. Z to lunch to discuss, and that counted as an unsolicited offer without a firm monetary value.

"50 is not enough, the bigger point is they have zero track record and are starting from scratch with a product nobody seems to want."

"with a product nobody seems to want."
You're going to have to do better than that. Who is Nobody and where does he live?

"big pharma buys private companies all day long, if the product was a 500 mil a year cash cow big pharma would have bought in a heartbeat. they are using cemp money to try to market this....bullskit. "
Yeah, but the point is that you need to show that they are making 500m a year.

Looks like Morgan Stanley, who put this deal together couldn't get many interested at the Morgan stanley event. Unreal

50 is not enough, the bigger point is they have zero track record and are starting from scratch with a product nobody seems to want.

big pharma buys private companies all day long, if the product was a 500 mil a year cash cow big pharma would have bought in a heartbeat. they are using cemp money to try to market this....bullskit.

there will be lawsuits, guaranteed. As far as the pharma offer, it is odd that there was not a follow up. if a pharma was serious they would not make an offer without DD including really taking a deep dive into all the data from the studies.
That firm is a class action firm.

there will be lawsuits, guaranteed. As far as the pharma offer, it is odd that there was not a follow up. if a pharma was serious they would not make an offer without DD including really taking a deep dive into all the data from the studies.
That firm is a class action firm.

The fact is that BP messes up rollouts ALL THE TIME. Arna and Eisai was a major blunder. They are not better.

And once again -- big pharma doesn't want to take the risk on a FQ. They'd demand too much premium. Big pharma is cautious as a rule. So they'd either buy the company or not do anything. They wouldn't do a partnership. So you're left with Eisai and co. which are not going to be any better than hiring your own salesforce.

You stated last year that having a sales force before approval is a major blunder. Well, it is. But now you say that 50 (to start) isn't enough. But they can't train a lot of salespeople that quickly (apparently). The strategy makes 100% sense.

What lawsuits? You mean this one: http://www.prnewswire.com/news-releases/shareholder-alert-monteverde--associates-pc-announces-an-investigation-of-cempra-inc----cemp-300516776.html?

That's just a fake lawsuit.. an advertisement. Look at the link they give: http://monteverdelaw.com/investigations/m-a/.

You cannot take these people seriously. It doesn't help your credibility when you mention "lawsuits" as if they were real and not advertisements.

They only filed one prelim proxy, etc.

I don't think they did appropriate DD, however, and I mentioned this to you and everyone on SA. They discarded an email from an international pharma because it didn't have a price tag. Now that is worthy of a (real) lawsuit.

I keep saying that the market isn't pricing this accurately but you keep saying they are trading under cash.

It is a little tiring.

Actually they are trading only slightly under net cash.

Looks that way to me too Johnny.



"Cemp should hire a great CEO and spend the 75 mil to get oral approved, instead they cede control to a flaming pile of crap."

Here comes the lawsuits... It begins.

Not to many positive mergers result in a negative 25% market cap.

It is never a smart strategy for a small biotech to market their own products, the upfront losses are staggering.

This deal is so bad it is trading under cash. They say MS shopped this to 90 companies and this was the best they could do.

Will be interesting to read the full disclosure by MS because they could also be liable in lawsuits.

IF Soli is as easy to approve as you say it is they should cut staff to bare minimum and spend the 70 mil. If it is a success it will be a blockbuster and large pharma will swallow them up.

The cash, tax loss, patents, Japan trials, and all the 600 mil in RD and data are currently worth less than the net cash on hand...

Absence of evidence isn't evidence of absence, but it's hard to tell just how much lying is going on. They DID submit a 2K patient safety study and it was turned down by the FDA. If you see BARDA fund a part of the safety study, the stock should explode.

I really cannot trust Cempra's analysis one way or the other. According to Japan's public clinicaltrials site, there are three soli trials, but Cempra keeps saying one CABP and doesn't mention the others. And how many patients will it enroll? No one (at least investors) know. Half of those patients can be added to the safety study. Maybe even you could add patients from the non-CABP studies because after all the FDA did count people from different studies to the current overall database.

Let's say there are in total 1.2K patients being treated in all 3 studies. So that reduces the sum by 20%. Assuming you trust the 75m figure, then that is 60m. And BARDA already committed more than this on the pediatric program -- $68.2m. I don't know if they'll foot the bill 100%, but maybe half-way. Then get Menarini to pay the other half for a contract. They are already paying for half of the CABP Baxdela trial, which maybe costs something like $20-$25m.

It's totally do-able.

About the salespeople: https://www.sec.gov/Archives/edgar/data/1461993/000119312517281202/g438060ex99_1s11g1.jpg -- sales force to expand based on adoption. A smart build-out strategy.

They have stated they want non-dilutive funding from the start -- going back to January. My article (you skimmed over it... I know it!) says that BARDA can handle a large part of it. They are already paying over $33M for the P2/3 pediatric trial... that is almost $90K per patient. And BARDA designed a part of the safety study (we don't know how much). Why wouldn't they fund a big part of it?

They have already hired some salespeople. The jobs portal is old. If you look on LinkedIn you can find them.

It is not 2022. It is 2021, and it is sandbagging so they don't get sued. Look at my article to understand why. I don't want to keep repeating myself!

50 is probably a little light but 70 is what a few people tell me is sufficient. What is your number and reasoning?!?

From the slide deck from MS

SOLITHROMYCIN (CABP)
• Pre-approval solithromycin patient request reduced to 6,000 to respond to CRL
• Trial to be conducted with 5-day, oral dosing only
• Oral-only safety study could support approval of oral solithromycin, with option to
seek future IV approval
• Oral-only protocol reduces cost, increases efficiency and utilizes dosing regimen
that appeared to have a lower ALT profile in Phase 3
• Seeking non-dilutive funding to support study


Looks like these Bozo's are also hiring 50 salespeople in US. UNREAL


http://files.shareholder.com/downloads/AMDA-RCGC8/5169787846x0x956369/CCB21B72-488B-4EAA-808C-31D3177B94B9/Cempra_FINAL_Sept_2017_Investor_Slides.pdf


These guys think so little of SOLI they wont fund the study with the cash they have.

basically they are saying they are getting hoping and praying the Government will pay for Soli trial..

This other drug is wont see the light of day until the end of 2018 and that is where all the cash goes. Another terrible presentation on the way from these blowhards.

AG - Cemp slide deck for MS out. First opinion is it is not long enough

I know you are long and most likely have a lot invested. So did we. Well, we still do but luckily let some fly in 30's.

My friend was not so lucky and is down 7 figures.

Read the proxy, earliest they expect soli is 2022. They already amended proxy.

The time for the powerpoint was at the announcement. Thinking about adding 200k shares here just based on Soli even if it takes 36 months.

Your big pharma is ok, but it is a mostly Italian EU company. It does not look they hired any of the 70 reps for the US and most likely will have to double that. How is that risk spread out?

You are looking through rose colored glasses, I do it quite a bit myself.

Hopefully these dummies do a better presentation this week at MS

To answer your questions/complaints:

"Have you read the 800 plus pages of crap, just when I had someone spend half a day printing that garbage they updated it so one has to play hide and seek finding the changes."

I don't know where/when they updated it. There is only one preliminary proxy SEC filing. Not sure what you are seeing here.


"If this is so hot why is CEMP getting very little in return, Cemp has the cash, Cemp is on NASDAQ, CEMP also has a valuable tax benefit to a profitable company, CEMP has valuable patents."

I agree they do, but Baxdela is also very valuable.


"They should have had a persuasive 30-to 40 page powerpoint presentation highlighting the benefits."

They'll have a presentation that probably just regurgitates some parts of the proxy. At the risk of sounding like a know-it-all, I don't think the presentation will be any better than my article. But maybe when the company says it, it might make more people aware of it. Or it might not. My latest article has been read by


"The modeling I read does not have Soli hitting the market until 2022.. If it only costs 75 mil to get oral completed in less than a year why dont they just do that. They will have a blockbuster drug at that point. Not to mention get in and hire some big hitters to sue the FDA. There is a plan."

Dr. Z said it would take 2-3 years and 75 million and the proxy says 2021 (not 2022), but I have no reason to believe any of these numbers are correct.


If they do not do some sort of merger, Cempra management does not get golden parachutes, which is hundreds of thousands of dollars for each top dog. There is also a nominal decrease in risk of solithromycin not getting approval even after the 6,000 patient trial is run, which is part of their merger rationale, but I don't believe that the risk is there.

Other than that, there is the synergy in the merger in several respects:
* Combined SG&A will be reduced compared to separate SG&A.
* The combined company will have more freedom to really be able to fully market Baxdela. 90m from Oberland Capital is a lot, but possibly not ideal.
* Once solithromycin is approved, they already have a sales force to sell it, for many of the same indications, but in complementary areas and similar advantages in those areas. For example,
++ Solithromycin is supposed to replace two drugs.
++ Baxdela is supposed to replace two or more drugs.
++ They are both mutation-resistant. They have some potentially complementary contra-indications.
++ Safety will be touted for both.
++ Baxdela will start in mostly hospital use for serious skin infections (i.e.: ABSSSI) and very serious CABP, while solithromycin is really intended as a replacement for azithromycin.


"Why did the idiot board go along with prabda and most likely hundreds of millions of dollars hiring a salesforce for a product that wasn't even approved?"

You might have seen my post on SA. It was simply foolishness by Prabha combined with monetary incentives to waste money in this way. They got bonuses for prepping a sales force before approval! See page 202 to the top of page 212.


"Didn't she say after the manufacturing issue that the delay was fine because the product would have been best launched 6 months later when doctors would be more receptive because of flu season."

It was 100% spin, what can I say. If they had approval in December and a sales force in place, they would have caught the most critical part of the 2016-2017 CABP season via sample packs, which (like the flu season) peaks between December and February. But she is no longer CEO.


"Your big pharma is big in Italy and some of EU but they don't have a big presence here. 70 reps is a start but more than likely double that will be needed. And the big question is how much risk they take rolling this out."

I've spoken with a few people who think 70 reps is just fine to start with. I'm sure they will increase that over time. All those reps need training, and they don't even have a CEO yet.


"Why isn't a big US pharma on this, those reps would have multiple products to showcase. Right now, your big pharma is not impressive at all"

Menarini has almost 17,000 employees. A lot of those work in the area of manufacturing. Definitely not a Pfizer though. But guess what.... Pfizer was partially responsible for the Cempra CRL as their manufacturing plant wasn't up to snuff for the FDA!

As for the US, can you give me an example of a big pharma selling someone else's antibiotic successfully? The fluoroquinolones that are being used by the dozens of millions in prescriptions every year are almost all generic, so it doesn't look great initially. Big pharma doesn't like the risk. What usually happens is a buyout, not a partnership (Cubist eating Optimer, Merck eating Cubist, Pfizer buying Astrazeneca antibiotics last year, etc.), because half-measures make no sense here.

So Melinta wasn't bought out. But you have no way of knowing if that wasn't a possibility.

"I hope I am wrong but these Cemp people are idiots as far as I can see. Why would they agree to pay 8 mil if the deal doesn't go through, that is bullshit."

I thought it was 5, but anyway, that is customary to account for potential lost opportunities. Melinta would potentially be out of other deals due to this merger... like a buyout by a big pharma!!!


"And to think that this is trading underwater if liquidation value is crazy. They might have to reverse split the stock just to meet Nasdaq requirements."

I do believe the stock is substantially undervalued. That is based on what the potential is based on my analysis of the science and competitive advantages of Baxdela and solithromycin, not what the stock market or even some big shots from big pharma think it is worth. Eventually, with good management execution, the market will catch up.

They are not that big in the US. Plus it is yet to be seen what risk they are assuming the first few years to market this.

Why did the idiot board go along with prabda and most likely hundreds of millions of dollars hiring a salesforce for a product that wasn't even approved?

Salary, car, computers, insurance and severance for what, nothing. The lawyers suing Cemp should drill down on that.

Didn't she say after the manufacturing issue that the delay was fine because the product would have been best launched 6 months later when doctors would be more receptive because of flu season.

Your big pharma is big in Italy and some of EU but they don't have a big presence here. 70 reps is a start but more than likely double that will be needed. And the big question is how much risk they take rolling this out.

Why isn't a big US pharma on this, those reps would have multiple products to showcase. Right now, your big pharma is not impressive at all

I hope I am wrong but these Cemp people are idiots as far as I can see. Why would they agree to pay 8 mil if the deal doesn't go through, that is bullshit.

And to think that this is trading underwater if liquidation value is crazy. They might have to reverse split the stock just to meet Nasdaq requirements

That is true, but if Soli is so promising wouldn't a pharma that was actually making money utilize the losses. If it only costs 75 mil for Soli oral trial this would be a no Rainer for big pharma.